RxDoctor Payments Data

Wilson Ginete

Interventional Cardiology · Duluth, MNNPI 1922055607

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (58.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Abbott at 54.6% of the total. 2025 is the largest year on record at $2,389, 2.9 times the $817 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.

$4,456in general payments, 2019–2025

Across 36 payments — averaging $123.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$862
  • Boston Scientific$840
  • Abiomed$137
  • Shockwave Medical, Inc$98
  • Endotronix, Inc.$75
  • plus $12 from 1 others
$401,025in research payments, 2019–2025

Across 202 payments — averaging $1985.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$137K
  • Cardiovascular Systems Inc.$106K
  • Medtronic$54K
  • Bayer$53K
  • CSL Behring$31K
  • Shockwave Medical, Inc$16K
  • plus $5K from 1 others

What the payments were for

  • Travel & lodging$2,60458%
  • Food & beverage$1,84041%
  • Education$120%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,456 in reported general payments places this provider in the 45th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$85,153
Medicare patients
538
Services billed
960

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$159,574
XareltoRivaroxaban106$96,183
JardianceEmpagliflozin109$91,426
Repatha SureclickEvolocumab63$62,183
EntrestoSacubitril/Valsartan58$51,204
BrilintaTicagrelor34$25,564
Repatha PushtronexEvolocumab15$9,760
Prasugrel Hcl50$4,830
Metoprolol Succinate245$3,983
ClopidogrelClopidogrel Bisulfate199$2,903
Atorvastatin Calcium240$2,603
Rosuvastatin Calcium194$2,499
Ezetimibe123$1,766
Isosorbide Mononitrate ErIsosorbide Mononitrate108$1,592
Flecainide Acetate36$1,578

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →